ArticleCurrent cancer drug targets2025
Single-Cell Transcriptomics: Technical Advances, Applications and Challenges in Cancer Drug Discovery.
Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advancements in technology, single-cell RNA sequencing has emerged as a power-ful tool in cancer drug discovery. This technique enables the construction of gene expression profiles at the individual cell level, offering detailed insights into cellular heterogeneity and molecular path-ways involved in tumor development. It enables researchers to gain a deeper understanding of tumor heterogeneity. Researchers can study cell subpopulations and gene expression patterns. This under-standing helps in identifying potential drug targets. Additionally, it aids in predicting therapeutic responses. This high-resolution gene expression analysis provides a new perspective and oppor-tunity for cancer drug development, which is expected to accelerate the discovery and development process of new anti-cancer drugs. This article provides a comprehensive overview of the basic pro-cesses and developmental trajectory of single-cell RNA sequencing technology, with a particular emphasis on its applications in various aspects of cancer drug discovery. It also addresses the chal-lenges faced by single-cell RNA sequencing and potential future directions. This review aims to enhance readers' understanding of single-cell sequencing, inspire new ideas for oncology drug de-velopment, and support the translation of clinical research into practice, ultimately enabling physi-cians to design more precise and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.